Header image
Simplifying Oncology Care
          Home    About APS    Pipeline    FAQs    Investors    Media    Contact Us
 
 
 
 
 
 
Proposed Mechanism of Action for AP002

Applied Protein Sciences’ (APS) lead compounds AP001 and AP002 demonstrate favorable results for the prevention and treatment of chemotherapy and radiation induced mucositis. Specifically, AP001 and AP002 act at the stem cell level as therapeutic agents for resolving mucosal injuries through targeting epithelial cell regeneration and initiating cyto-protective measures. The effectiveness of AP001 and AP002 can be traced to three aspects:

  1. Protecting mast cells against cytotoxic treatment
  2. Inhibiting production of pro-inflammatory cytokines such as IL-1β, IL-6 and TNF-α, and
  3. Inhibiting enterocyte apoptosis through attenuation of the Bax gene and stimulation of Bcl-2 which exacerbate mucositis.
Based on these findings, AP002 could be a 'standard of care' for the prevention and treatment of radiation and chemotherapy induced mucositis. The illustration below provides a complete picture of the dynamic process involved in the development of mucositis and the prophylactic role played by APS cyto-protective drugs AP001 and AP002 to inhibit the progression of both oral and GI mucositis.

Proposed Mechanism of Action of AP002 image
About Mucositis

Chemotherapy agents and radiation used to treat cancer often severely damage the mucosal lining, leading to mucositis. No preventive medications are available and mucositis interferes with an optimal cancer treatment. Annually, more than 400,000 patients are at risk of developing oral mucositis and mucositis adds $2B+ to the overall healthcare system in the USA.